Skip to main content
TipRanks
Go Ultimate75% OFF

Evgen Pharma (TCF) AI Stock Analysis

4 Followers
GB:TCF

Evgen Pharma

(LSE:TCF)

Select Model
Rating:40Underperform
Price Target:GBX 0.16â–¼(-1.82% Downside)
Action:downgraded
Date:09/29/26

Financial performance weighs most heavily due to negligible revenue, sustained losses, and high cash burn despite a clean balance sheet. Weak technical signals with price below moving averages and low RSI add further downside pressure, while negative P/E limits valuation support.

Positive Factors
Proprietary drug-discovery platformOwnership of the Sulforadex platform gives Evgen a defined technology base from which to develop multiple therapeutics. Its application across oncology and inflammatory or disease areas may support a broader development strategy and create future partnering opportunities.
Negative Factors
Persistent operating lossesPersistent operating and net losses show that the company has not yet converted its development activities into sustainable profitability. The larger reported loss in 2026 increases uncertainty around the path to breakeven and may constrain internal funding for pipeline advancement.

Evgen Pharma (TCF) vs. iShares MSCI United Kingdom ETF (EWC)

-20%-10%0%10%20%30%40%GB:TCF-13.16%EWC+8.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 3.55M
Dividend Yield
―
Average Volume (3M)
2.77M
Price to Earnings (P/E)
-1.6
Beta (1Y)
0.83
Revenue Growth
―
EPS Growth
55.56%
Country
UK
Employees
9
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Evgen Pharma Business Overview & Revenue Model

Company Description

Theracryf Plc operates as a clinical-stage biotechnology firm, dedicated to advancing treatments for oncological diseases and various brain disorders affecting behavior. Its primary therapeutic asset, SFX-01, is currently progressing through Phase II...

How the Company Makes Money

Evgen Pharma is a clinical-stage biopharmaceutical company and, based on publicly available information, it does not appear to generate recurring product revenue from marketed drugs. Its typical monetization model is expected to be (i) partnering/lic...

Evgen Pharma Financial Statement Overview

Summary

Minimal revenue with persistent net losses and high cash burn, offset partially by a debt-free balance sheet.

Income Statement

25Negative

Balance Sheet

45Neutral

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue000396.00K442.00K0
Gross Profit-16.00K-16.00K-2.11M385.00K429.00K-16.00K
EBITDA-3.62M-3.67M-2.06M-3.55M-4.99M-3.15M
Net Income-3.53M-3.53M-1.94M-3.14M-4.04M-2.73M
Balance Sheet
Total Assets4.81M4.81M7.63M3.06M6.17M9.64M
Cash, Cash Equivalents and Short-Term Investments1.54M1.54M4.11M2.00M5.00M9.03M
Total Debt11.00K11.00K0000
Total Liabilities2.10M2.10M1.66M721.00K833.00K411.00K
Stockholders Equity2.72M2.72M5.97M2.34M5.34M9.23M
Cash Flow
Free Cash Flow-2.56M-2.56M-2.37M-3.00M-4.03M-2.56M
Operating Cash Flow-2.55M-2.55M-2.37M-3.00M-4.03M-2.56M
Investing Cash Flow916.00K916.00K-2.08M04.52M1.48M
Financing Cash Flow-7,000-7,0004.55M000

Evgen Pharma Technical Analysis

Technical Analysis SentimentNegative
Last Price0.17

Price Trends

50DMA0.18Negative
100DMA0.19Negative
200DMA0.20Negative

Market Momentum

MACD-0.00Positive
RSI11.96Positive
STOCH0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TCF, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.18, and below the 200-day MA of 0.20, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 11.96 is Positive, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:TCF.

Evgen Pharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:TCF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:SARGB:SAR47NeutralGBP 23.75M-6.04-188.01%――28.78%
GB:HEMOGB:HEMO46NeutralGBP 46.21M-3.70-409.57%――18.57%
GB:VALGB:VAL43NeutralGBP 1.85M-0.74-71.49%―-34.36%57.45%
GB:SCLPGB:SCLP42NeutralGBP 95.77M-4.51128.87%―-100.00%-30.39%
GB:TCFGB:TCF40UnderperformGBP 4.51M-1.65-93.92%――55.56%
GB:IMMGB:IMM39UnderperformGBP 18.06M-2.31-559.87%――5.62%

* Healthcare Sector Average

Performance Comparison

0%100%GB:TCFGB:IMMGB:SARGB:SCLPGB:HEMOGB:VALDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:TCF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:TCFEvgen Pharma0.17-0.02-13.16%
GB:IMMImmuPharma plc2.90-3.81-56.79%
GB:SARSareum Holdings14.501.5011.54%
GB:SCLPScancell Holdings79.00-15.50-16.40%
GB:HEMOHemogenyx Pharmaceuticals Plc670.00-10.00-1.47%
GB:VALValiRx plc0.14-0.11-45.10%

Evgen Pharma Corporate Events

Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements

TheraCryf advances lead addiction drug to clinic-ready stage as losses widen

Positive
Sep 28, 2026

TheraCryf reported final results for the year to 31 March 2026, highlighting strong operational progress on its lead orexin-1 antagonist for addiction, which has advanced through late-stage preclinical development on time and budget. The company comp...

Business Operations and StrategyFinancial Disclosures

TheraCryf Sets Results Date as Lead Addiction Therapy Nears Clinical Readiness

Positive
Sep 14, 2026

TheraCryf plc, the biotech group developing treatments for addiction and neuropsychiatric conditions, is advancing a de-risked, best-in-class orexin-1 receptor antagonist through final pre-clinical trials and operates a virtual, partnership-focused d...

Private Placements and FinancingShareholder MeetingsStock Split

TheraCryf Wins Shareholder Backing for £1.05m Fundraise and Share Subdivision

Positive
Sep 7, 2026

TheraCryf plc, the biotech company developing treatments for addiction and other neuropsychiatric disorders, has secured shareholder approval for a capital raising of about £1.05 million through a placing and subscription. Investors also backed a sub...

Business Operations and StrategyPrivate Placements and Financing

TheraCryf raises £1.05m to advance addiction drug towards Phase 1 trials

Positive
Aug 20, 2026

TheraCryf plc has announced a proposed £1.05 million equity raise via a placing and subscription of new shares, priced at 0.18 pence each and directed to existing and new investors, to strengthen its balance sheet. The capital injection is intended t...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 29, 2026